H. pylori Diagnostic Kit Components
H. pylori diagnostic kits contain specific reagents and materials designed to detect either bacterial antigens, antibodies, or urease activity, with the exact components varying by test type.
Non-Invasive Test Kit Components
Stool Antigen Test Kits
The stool antigen test kits detect H. pylori antigens directly in fecal specimens and typically include 1:
- Collection container for stool specimen
- Extraction buffer/reagent to process the sample
- Test cassette or strip with monoclonal or polyclonal antibodies against H. pylori antigens
- Control reagents for validation
- Pipettes or droppers for sample application
Recent molecular diagnostic kits using multiplex RT-PCR technology contain 2:
- Sample collection tubes with stabilization buffer
- DNA extraction reagents
- RT-PCR primers targeting 23S rRNA and gyrA genes
- Fluorescent probes for detection
- Positive and negative controls
Urea Breath Test (UBT) Kits
These kits exploit H. pylori's urease enzyme activity and include 1:
- Labeled urea substrate (either ¹³C-urea or ¹⁴C-urea, typically 75 mg dose)
- Breath collection bags or tubes (baseline and post-ingestion samples)
- Tablet or liquid formulation of the labeled urea
- Test meal components (though newer protocols may omit this)
- Collection timing instructions (typically 10-30 minutes post-ingestion)
Serological Test Kits (ELISA)
These detect anti-H. pylori IgG antibodies and contain 1, 3:
- Microtiter plates pre-coated with H. pylori antigens (often glycine extracts or outer membrane proteins)
- Conjugate reagent (enzyme-labeled anti-human IgG)
- Substrate solution for color development
- Wash buffer
- Stop solution
- Positive and negative control sera
Near-Patient/Point-of-Care Test Kits
Rapid whole blood or serum tests include 1:
- Lancet for finger-prick blood collection
- Test cassette with immunochromatographic membrane
- Sample application pad
- Buffer solution
- Control line indicators
Invasive Test Kit Components (Endoscopy-Based)
Rapid Urease Test (RUT) Kits
Available in multiple formats 4:
Gel-based tests (CLOtest, Hpfast):
- Agar gel medium containing urea
- pH indicator (phenol red)
- Biopsy well for tissue placement
- Sealed container to prevent contamination
Paper-based tests (PyloriTek™):
- Paper strip impregnated with urea and indicator
- Protective casing
- Reading window for color change detection
Tablet tests:
- Compressed urea tablets with pH indicator
- Reaction chamber
All RUT kits require at least 10⁴ organisms for positive results and are read between 1-24 hours depending on the specific kit 4.
Culture Test Components
For bacterial isolation 4:
- Transport medium (Stuart's medium, normal saline, or chocolate agar slants)
- Selective culture media with antibiotic combinations
- Microaerophilic incubation system
- Temperature control (specimens must be kept at 4°C if delayed processing)
Molecular Diagnostic Kits (PCR-Based)
For intragastric fluid or biopsy specimens 5:
- Sample collection tubes with preservation buffer
- DNA extraction reagents
- PCR primers targeting H. pylori-specific genes
- Probes for clarithromycin resistance mutations (23S rRNA)
- Amplification reagents
- Detection system (real-time PCR platform)
Key Clinical Considerations
Important caveats: Proton pump inhibitors, antibiotics, and bismuth compounds must be discontinued before testing with UBT, stool antigen tests, or RUTs, as they reduce bacterial load and cause false-negative results 6. Serological tests remain positive long after eradication (creating a "serologic scar") and should not be used to confirm active infection 6.
Test selection algorithm: For initial diagnosis in primary care settings, use either UBT or stool antigen test (both achieve >90% sensitivity and specificity) 1. Reserve endoscopy-based tests for patients with alarm symptoms, those requiring culture for antibiotic susceptibility testing after treatment failure, or when endoscopy is clinically indicated 4.
The newest molecular kits can detect antibiotic resistance patterns (clarithromycin and fluoroquinolone) directly from stool samples within hours, achieving >90% concordance with traditional susceptibility testing 2, representing a significant advancement for tailored therapy selection.